 VICTORIA, British Columbia--BUSINESS WIRE--- IPA POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. the Company or IPA NASDAQ: IPA TSX VENTURE: IPA a leader in full-service, therapeutic antibody discovery and development, today announced financial results for the third quarter of its 2021 fiscal year ended January 31, 2020. Q3 Fiscal 2021 Financial Highlights: Increased revenue for the nine months ended January 31st, 2021 by 32 to 13,035,522. Record adjusted EBITDA for the nine months ended January 31st, 20 